Transgene
Transgene is an integrated biotechnology company based in France that specializes in the research and development of innovative immunotherapeutic products aimed at treating cancers and chronic infectious diseases. The company focuses exclusively on clinical research and the development of therapeutic vaccines, with notable programs including TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Transgene's product pipeline also features additional candidates such as TG4001, TG1050, and TG6002. With expertise spanning all stages of product development, the company manages processes from initial research through to the manufacturing of clinical batches and the execution of clinical trials.
1 past transactions
ElsaLys Biotech
Series A in 2013
ElsaLys Biotech is a clinical-stage biotechnology company based in Lyon and Strasbourg, France, that specializes in the design and development of therapeutic antibodies aimed at treating tumors and their associated immune and vascular microenvironments. Founded in 2013, ElsaLys Biotech is focused on advancing its research and development programs, which include multiple oncology initiatives and ophthalmology projects. The company's innovative approach seeks to harness the potential of monoclonal antibodies to improve therapeutic outcomes for patients facing various cancers and eye diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.